Dermatophytic Onychomycosis Treatment Market – Insights

Dermatophytic Onychomycosis, also known as tinea unguium, is a fungal nail infection caused by dermatophytes. Dermatophytes are fungi that require keratin for growth. Dermatophytic Onychomycosis is the most common nail infection and it affects toenails and fingernails.

The global dermatophytic onychomycosis treatment market is estimated to account for US$ 7,851.4 Mn in terms of value by the end of 2027.

Global Dermatophytic Onychomycosis Treatment Market: Drivers

Increasing prevalence of dermatophytic onychomycosis is a major factor boosting growth of the global dermatophytic onychomycosis treatment market over the forecast period. For instance, the study, ‘Dermatophytosis: Prevalence of Dermatophytes and Non-Dermatophyte Fungi from Patients Attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia’ published in the journal Dermatology Research and Practice in October 2018, demonstrated that the prevalence of dermatophytosis was 66.98% in Ethiopia.

Moreover, increasing prevalence of psoriasis is also expected to boost the market growth. For instance, the study, ‘The prevalence and etiological factors of onychomycosis in psoriatic patients’, published in the journal Advances in Dermatology and Allergology in April 2018, demonstrated a relatively high prevalence of onychomycosis in patients with psoriasis.

North America region held dominant position in the global dermatophytic onychomycosis treatment market in 2018, accounting for 45.8% share in terms of value followed by 2027.

Figure 1. Global Dermatophytic Onychomycosis Treatment Market Value (US$ Mn), by Region, 2018

Dermatophytic Onychomycosis Treatment  | Coherent Market Insights

Global Dermatophytic Onychomycosis Treatment Market: Restraints

Antifungal drugs used in the treatment of dermatophytic onychomycosis have certain side effects such as headache, dizziness, nausea, and stomach ache. Moreover, the topical agents also cause rash and itchiness in the surrounding skin. These side effects are expected to hamper growth of the global dermatophytic onychomycosis treatment market.

Moreover, availability of alternative treatment options such as Vicks Vapour Listerine and tea tree oil for the treatment of nail infections is also expected to hinder the market growth.

Global Dermatophytic Onychomycosis Treatment Market: Opportunities

The identification of the infectious agent in onychomycosis, at least at the genus level, plays major role in the treatment prescription for dermatophytic onychomycosis. Key players in the market can focus on development of dermatophyte strip tests for rapid detection and diagnosis of the disease.

Increasing geriatric population is also expected to offer lucrative growth opportunities for players in the global dermatophytic onychomycosis treatment market. Toenail onychomycosis is common in people aged 60 and above. According to the World Health Organization, the proportion of the world's population over 60 years was 12% in 2015 and is expected to reach 22% in 2050.

Dermatophytic Onychomycosis Treatment  | Coherent Market Insights

Nail Paints segment in the global dermatophytic onychomycosis treatment market was valued at US$ 2,713.0 Mn in 2018 and is expected to reach US$ 6,086.0 Mn by 2027 at a CAGR of 9.5% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing increasing M&A activities. For instance, in January 2018, Viamet Pharmaceuticals entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals.

Key players in the market are focused on conducting clinical trials in order to expand their product portfolio. For instance, in January 2018, Novan announced to present the Phase II efficacy and safety data for SB208, a topical, silicone-based gel under development for the treatment of fungal infections of the skin and nails at the Winter Clinical Dermatology Conference.

Global Dermatophytic Onychomycosis Treatment Market: Competitive Landscape

Major players operating in the global dermatophytic onychomycosis treatment market include, Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.

Global Dermatophytic Onychomycosis Treatment Market: Key Developments

Key players in the market are focused on conducting clinical trials in order to expand their product portfolio. For instance, in December 2019, Moberg Pharma AB announced that MOB-015 (topical terbinafine) met both primary and key secondary endpoints of the clinical Phase 3 study that assessed the efficacy and safety of MOB-015 in patients with mild to moderate distal subungual onychomycosis.

Key players in the market are also focused on acquiring distribution rights of products to enhance their market share. For instance, in September 2018, Cipher Pharmaceuticals Inc. acquired the exclusive rights to commercialize, promote, sell, and distribute MOB-015 from Moberg Pharma in Canada for treatment of onychomycosis.

Nail onychomycosis is a fungal infection is caused by a trichophyton rubrum, trichophyton mentagrophytes, and in some cases it is caused by yeasts and molds. The major factors responsible for nail onchomycosis infection is increased exposure to worm and moist environment which leads to perfect condition for fungus to grow and proliferate. The major symptoms of onychomycosis comprises of white and yellow spots under the nail leading to discoloration, nail thickening, and formation of crumbling edges on the nail.

Key features of the study:

  • This report provides in-depth analysis of the global dermatophytic onychomycosis treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global dermatophytic onychomycosis treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Janssen Global Services, LLC (Johnson & Johnson Services, Inc.), Anacor Pharmaceuticals, Inc., NovaQuest Capital Management, L.L.C., and Novan, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global dermatophytic onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatophytic onychomycosis treatment market

Detailed Segmentation:

  • Dermatophytic Onychomycosis Treatment Market, By Product Type:
    • Tablets
      • Rx
      • OTC
    • Mail Paints
      • Rx
      • OTC
  • Dermatophytic Onychomycosis Treatment Market, By Treatment:
    • Oral
    • Topical
  • Dermatophytic Onychomycosis Treatment Market, By End User:
    • Hospitals
    • Clinics
    • Independent Pharmacies
    • Mail Order Pharmacies
    • Drug Stores
  • Dermatophytic Onychomycosis Treatment Market, By Region:
    • North America
      • By Product Type:
        • Tablets
          • Rx
          • OTC
        • Mail Paints
          • Rx
          • OTC
      • By Treatment
        • Oral
        • Topical
      • By End User
        • Hospitals
        • Clinics
        • Independent Pharmacies
        • Mail Order Pharmacies
        • Drug Stores
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Tablets
          • Rx
          • OTC
        • Mail Paints
          • Rx
          • OTC
      • By Treatment
        • Oral
        • Topical
      • By End User
        • Hospitals
        • Clinics
        • Independent Pharmacies
        • Mail Order Pharmacies
        • Drug Stores
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Tablets
          • Rx
          • OTC
        • Mail Paints
          • Rx
          • OTC
      • By Treatment
        • Oral
        • Topical
      • By End User
        • Hospitals
        • Clinics
        • Independent Pharmacies
        • Mail Order Pharmacies
        • Drug Stores
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Tablets
          • Rx
          • OTC
        • Mail Paints
          • Rx
          • OTC
      • By Treatment
        • Oral
        • Topical
      • By End User
        • Hospitals
        • Clinics
        • Independent Pharmacies
        • Mail Order Pharmacies
        • Drug Stores
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Tablets
          • Rx
          • OTC
        • Mail Paints
          • Rx
          • OTC
      • By Treatment
        • Oral
        • Topical
      • By End User
        • Hospitals
        • Clinics
        • Independent Pharmacies
        • Mail Order Pharmacies
        • Drug Stores
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Tablets
          • Rx
          • OTC
        • Mail Paints
          • Rx
          • OTC
      • By Treatment
        • Oral
        • Topical
      • By End User
        • Hospitals
        • Clinics
        • Independent Pharmacies
        • Mail Order Pharmacies
        • Drug Stores
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Valeant Pharmaceuticals International Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Galderma S.A.
    • Novartis AG
    • Pfizer Inc.
    • Moberg Pharma AB
    • Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
    • Anacor Pharmaceuticals, Inc.
    • NovaQuest Capital Management, L.L.C.
    • Novan, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Treatment
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • Merger and Acquisition Scenario
    • PEST Analysis
  4. Global Dermatophytic Onychomycosis Treatment Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Tablets        
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Rx
        • OTC
    • Nail Paints
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Rx
        • OTC
  5. Global Dermatophytic Onychomycosis Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Dermatophytic Onychomycosis Treatment Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Independent Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Mail Order Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Drug Stores
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Dermatophytic Onychomycosis Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Valeant Pharmaceuticals International Inc. *
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Galderma S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Moberg Pharma AB
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Anacor Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NovaQuest Capital Management, L.L.C.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novan, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 42 market data tables and 40 figures on "Dermatophytic Onychomycosis Treatment Market” - Global forecast to 2027.